Why ISO 13485 Internal Audits Matter for MDSAP
For a medical device manufacturer, an internal audit is not simply a requirement to be completed before the certification auditor arrives, but if done well, it is the organization’s own independent test of whether the quality management system can consistently protect the patient, satisfy regulatory requirements and provide reliable evidence of control. That purpose becomes even more important when the organization is preparing for the Medical Device Single Audit Program (MDSAP).
ISO 13485 provides the quality management system foundation. MDSAP uses that foundation but applies it through a regulatory audit model that incorporates the applicable requirements of participating jurisdictions. A manufacturer that conducts only a clause-by-clause conformity audit may therefore be ISO 13485 compliant on paper and still be poorly prepared for MDSAP. The internal audit program must test the connections among processes, products, risks, records and regulatory obligations. ISO 13485 and MDSAP are therefore related, but not identical.
ISO 13485 Internal Audit Requirements and MDSAP
ISO 13485 is an international quality management system standard written specifically for medical devices and for regulatory purposes. Clause 8.2.4 requires the organization to conduct internal audits at planned intervals to determine whether the quality management system conforms to planned arrangements, the standard, and the organization’s own requirements, and whether it is effectively implemented and maintained. The audit program is to consider the status and importance of processes and areas, as well as the results of previous audits. Auditor objectivity, records, timely correction and corrective action, and verification of action taken are essential parts of the requirement.
MDSAP is not another management system standard. It is a structured audit approach under which a recognized auditing organization may conduct one regulatory audit that addresses the relevant requirements of the participating regulatory authorities for example, Australia, Brazil, Canada, Japan and the United States. A single audit does not mean one universal set of regulations. It means that applicable country-specific requirements are examined through one coordinated audit model.
This distinction matters. An ISO 13485 internal audit may ask, ‘Does the complaint process meet Clause 8.2.2?’ An MDSAP-oriented internal audit must also ask whether the complaint was assessed against reportability criteria in every market where the device is supplied, whether the decision was made within the required time, whether any advisory notice or field action was properly controlled, and whether the information entered the risk-management and CAPA processes. Therefore, the intend is to think in audit trails, not isolated clauses.
Follow Audit Trails, Not Isolated Clauses
The MDSAP audit model is process based and follows defined linkages. Its major process areas include management, device Marketing authorization and facility registration, measurement, analysis and continual improvement, medical device adverse events and advisory notices reporting It also includes design and development, production and service controls and purchasing. The audit is designed to follow evidence from one process into another. That approach should influence the manufacturer’s internal audit program. Instead of auditing document control on Monday, purchasing on Tuesday and complaints on Wednesday as unrelated subjects, select representative devices, changes, suppliers, complaints or nonconformities and trace them through the system. For example, a complaint involving a failed component can provide an audit trail through complaint intake, evaluation and investigation (Clause 8.2.2); regulatory reporting and advisory-notice decisions (clause 8.2.3 and applicable national requirements); analysis of data and detection of adverse trends (clause 8.4); risk-management review and design or process implications (clauses 7.1 and 7.3); supplier controls and purchasing information (clause 7.4); and correction, CAPA and effectiveness review (clauses 8.3, 8.5.2 and 8.5.3).
Build a Risk-Based ISO 13485 Internal Audit Program
This is a much stronger test of effectiveness. It also reflects the way regulatory auditors think. A weakness rarely remains confined to one procedure. A missed complaint trend may reveal problems in data analysis, risk management, supplier control and management oversight at the same time. The idea is to build the audit program around risk and regulatory importance. Clause 8.2.4 expects the audit program to consider the status and importance of the processes and areas to be audited, and previous audit results. This is a clear basis for risk-based planning. ‘All clauses once a year’ may be easy to schedule, but it is not necessarily an effective audit program.
Processes with a direct effect on device safety or regulatory compliance should receive greater depth or frequency. These may include sterile barriers, software validation, special processes, design transfer, complaint handling, adverse-event reporting, supplier controls, traceability, product release and CAPA. The organization should also consider new products, transfers, acquisitions, major changes, recurring nonconformities, supplier deterioration, adverse trends and prior external-audit findings.
Risk-based does not mean that low-risk processes are ignored. It means that audit resources are applied intelligently. The program should document why certain processes are audited more frequently, why particular products or sites were sampled, and how previous results influenced the next cycle. An MDSAP auditor should be able to see that the internal audit program responds to the actual risk profile of the business.
Include Applicable Regulatory Requirements
The need is to add the applicable regulatory requirements. ISO 13485 repeatedly refers to applicable regulatory requirements. An internal audit cannot verify conformity unless the auditors know what those requirements are. The organization therefore needs a maintained regulatory matrix or equivalent method that identifies the markets served, device classifications, licenses or registrations, reporting obligations, record-retention periods, language or labeling requirements, and responsible functions.
This matrix should be used when preparing audit criteria and sampling records. If a device is marketed in Canada, Brazil and the United States, the auditor should not stop after confirming that an ISO procedure exists. The auditor should verify that the current authorizations are in place, changes have been assessed for notification or approval, establishment information remains accurate, and reportable events have been handled under the applicable jurisdictional rules.
FDA QMSR and ISO 13485 Alignment
For U.S. manufacturers, the regulatory context changed materially on February 2, 2026, when FDA’s Quality Management System Regulation (QMSR) became effective. QMSR incorporates ISO 13485:2016 by reference, with additional FDA requirements and the FD&C Act controlling where a conflict exists. FDA also replaced the former QSIT inspection approach with its updated inspection process. This alignment makes a mature ISO 13485 system more valuable, but it does not eliminate U.S.-specific obligations. Internal auditors must understand both the incorporated standard and the regulatory additions.
Begin the MDSAP Audit with Management Responsibility
Top management auditing should be the start of the audit. That way down the line at workplaces this can be verified. Therefore, audit management responsibility first. MDSAP places strong emphasis on management responsibility because leadership provides the resources and decisions that hold the system together. Internal audits should test more than whether management-review minutes exist. Under clauses 5.1 and 5.6, auditors should evaluate whether top management receives meaningful information, acts on it and ensures the continuing suitability, adequacy and effectiveness of the system.
Useful trails include overdue CAPAs, complaint trends, supplier performance, audit findings, regulatory changes, product nonconformities and resource constraints. Was management given accurate information? Were decisions assigned, resourced and completed? Did management recognize a systemic issue before an external auditor did? Repeated problems accompanied by polished management-review minutes are evidence that the review may be ceremonial rather than effective.
Strengthen High-Value MDSAP Audit Trails
The spirit of the auditing clause from ISO 13485 seen with MDSAP implies strengthen the high-value audit trails to ensure:
- Measurement, analysis and improvement: this process is often the best starting point because it shows whether the manufacturer learns from its own data. Audit complaint handling, internal audits, nonconforming product, data analysis and CAPA as one system. Challenge the rationale for investigation and reportability decisions. Select closed CAPAs and verify effectiveness using subsequent performance data—not merely evidence that a procedure was revised or training was completed.
- Design and development: for devices subject to design controls, trace user needs into design inputs, outputs, verification, validation and transfer (Clause 7.3). Confirm that risk-management activities are integrated throughout development and that design changes are reviewed, verified or validated as appropriate, approved and assessed for regulatory impact. Include software, usability, cybersecurity and supplier-developed elements where applicable to the product.
- Production and service controls: follow a released device from approved specifications through production, inspection, acceptance, identification, traceability, storage and distribution (Clauses 7.5 and 8.2.6). For processes whose output cannot be fully verified later, examine validation, revalidation triggers, equipment, personnel qualification and process monitoring. Ask whether acceptance evidence can be linked to the person, equipment, method and current specification used.
- Purchasing and outsourced processes: clause 7.4 requires controls proportionate to the supplier’s effect on product quality. Internal auditors should test whether supplier classification drives selection, monitoring and reevaluation; whether purchasing information accurately states requirements; and whether changes are communicated and controlled. Outsourcing transfers work, not accountability. Sample critical suppliers and verify that poor performance leads to escalation, corrective action or reconsideration of approval status.
- Adverse-event and advisory-notice reporting: this regulatory process deserves deliberate sampling. Begin with complaints, service reports, returns, literature, distributor communications or trend signals that could involve serious injury, malfunction or public-health risk. Verify the reportability assessment, decision date, rationale, submission evidence, follow-up and linkage to CAPA and risk management. A sound decision should be reproducible from the record without relying on the memory of one regulatory specialist.
Make Internal Audit Evidence MDSAP-Ready
Make internal audit evidence MDSAP-ready A credible audit file should tell the story of what was tested and what was concluded. It should contain the audit objective, scope, criteria, auditor independence, processes and locations covered, samples selected, evidence reviewed, findings, conclusions and follow-up. Vague statements such as ‘procedure reviewed—acceptable’ do not demonstrate audit depth.
The organization should also be careful not to confuse a document review with an audit. Procedures may be compliant while practice is not. Internal auditors need access to records, personnel, electronic systems and the workplace. They should observe activities, interview process owners, sample objective evidence and follow trails across departmental boundaries.
A Practical MDSAP Readiness Method
A practical MDSAP-readiness method ensures that a manufacturer can progressively strengthen its internal audit program through the following six actions:
· Map the QMS processes to the MDSAP audit model and to the regulations of every market served.
· Create a risk-based audit schedule using product risk, process importance, change, performance and previous results.
· Train auditors in ISO 13485, the MDSAP process approach and the applicable jurisdictional requirements—not only in generic auditing technique.
· Use end-to-end audit trails built around real devices, complaints, changes, suppliers and CAPAs.
· Write findings against clear criteria and address systemic causes, not merely the isolated record sampled.
· Verify correction, corrective action and effectiveness, then feed significant results into management review.
A useful final step is a focused readiness audit conducted in the expected MDSAP sequence. This should not be a staged performance in which employees memorize answers. It should be an honest stress test of the system, including incomplete records, adverse examples and older files. The objective is to discover weakness while the organization still has time to act.
Common MDSAP Audit Weaknesses to Avoid
Common weaknesses to avoid:
· Auditing only against ISO 13485 and omitting country-specific regulatory criteria.
· Using the same checklist every year regardless of changes, risks or past results.
· Allowing auditors to audit their own work or areas for which they are directly responsible.
· Reporting findings without enough objective evidence to support correction and root- cause analysis.
· Closing CAPA on completion of tasks rather than demonstrated effectiveness.
· Failing to connect complaints, adverse events, risk management, design changes and supplier action.
· Treating management review as a presentation rather than a decision-making process.
Conclusion
In conclusion my thought is MDSAP readiness is not achieved by adding another checklist to the audit folder. It comes from using internal audits to test whether the entire management system works as an integrated regulatory system. ISO 13485 Clause 8.2.4 provides the mechanism; management commitment, competent auditors, risk-based planning and disciplined process trails give that mechanism value. The best internal audit is not the one that produces the fewest findings. It is the one that identifies weaknesses before they affect a patient, a customer or a regulatory authority. When internal audits follow the evidence across functions, challenge the effectiveness of controls and confirm jurisdiction-specific obligations, the manufacturer is not merely preparing for MDSAP. It is strengthening the system that MDSAP is intended to evaluate—and improving the assurance that safe and effective medical devices will consistently reach the people who depend on them.
__
About the Author:
Inderjit (IJ) Arora, Ph.D., is the Chairman of QMII. He serves as a team leader for consulting, advising, auditing, and training regarding management systems. He has conducted many courses for the United States Coast Guard and is a popular speaker at several universities and forums on management systems. Arora is a Master Mariner who holds a Ph.D., a master’s degree, an MBA, and has a 35-year record of achievement in the military, mercantile marine, and civilian industry.








